Perrigo Company plc Gain (Loss) on Disposition of Other Assets
Perrigo Company plc (PRGO) reported Gain (Loss) on Disposition of Other Assets of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnSaleOfOtherAssets · last filed 2026-02-26
- Perrigo Company plc gain (loss) on disposition of other assets for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Perrigo Company plc gain (loss) on disposition of other assets for the quarter ending 2024-12-31 was $2.10M, a 2000.00% increase year-over-year.
- Perrigo Company plc gain (loss) on disposition of other assets for the quarter ending 2024-09-28 was $26.00M.
- Perrigo Company plc gain (loss) on disposition of other assets for the quarter ending 2024-06-29 was $0.00, a 100.00% decline year-over-year.
- Perrigo Company plc gain (loss) on disposition of other assets for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Perrigo Company plc gain (loss) on disposition of other assets for fiscal 2024 was $28.10M, a 585.37% increase from fiscal 2023.
- Perrigo Company plc gain (loss) on disposition of other assets for fiscal 2023 was $4.10M, a 22.64% decline from fiscal 2022.
- Perrigo Company plc gain (loss) on disposition of other assets for fiscal 2022 was $5.30M.
| Period end | Gain (Loss) on Disposition of Other Assets 3 month | Gain (Loss) on Disposition of Other Assets 6 month | Gain (Loss) on Disposition of Other Assets 9 month | Gain (Loss) on Disposition of Other Assets 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | ||
| 2025-09-27 | $0.00 10-Q · filed 2025-11-05 | |||
| 2024-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $28.10M derived: sum of 2 quarters · filed 2026-02-26 | $28.10M derived: sum of 3 quarters · filed 2026-02-26 | $28.10M 10-K · filed 2026-02-26 |
| 2024-09-28 | $26.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $26.00M derived: sum of 2 quarters · filed 2025-11-05 | $26.00M 10-Q · filed 2025-11-05 | $26.10M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-29 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $0.00 10-Q · filed 2024-08-02 | $100.00K derived: sum of 3 quarters · filed 2026-02-26 | $100.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-30 | $0.00 10-Q · filed 2024-05-07 | $100.00K derived: sum of 2 quarters · filed 2026-02-26 | $100.00K derived: sum of 3 quarters · filed 2026-02-26 | $200.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $100.00K derived: sum of 2 quarters · filed 2026-02-26 | $200.00K derived: sum of 3 quarters · filed 2026-02-26 | $4.10M 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $100.00K derived: sum of 2 quarters · filed 2024-11-06 | $4.00M 10-Q · filed 2024-11-06 | |
| 2023-07-01 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $4.00M 10-Q · filed 2024-08-02 | ||
| 2023-04-01 | $3.90M 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $5.30M 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |